BG Medicine Inc
OTC:BGMD
Intrinsic Value
BG Medicine, Inc. is a life sciences company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BGMD.
BG Medicine Inc's market capitalization is 5.5k USD.
BGMD stock price is 0.0001 USD.
BGMD.
BGMD. Open DCF Valuation
BGMD. Open Relative Valuation
BGMD.
BGMD's long-term assets (2m USD) exceed its long-term liabilties (2m USD).
BGMD's short-term assets (2m USD) exceed its short-term liabilties (1m USD).
BGMD's ROE (Return on Equity) has significantly decreased in the last 3 years from -1 126% to -1 184%, and is approaching profitability.
BGMD's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -9 260% to -2 009%, and is approaching profitability.
BGMD has negative Operating Income for the last twelve months.
BGMD has negative Net Income for the last twelve months.
BGMD's ROE (Return on Equity) for the past 12 months is negative and is equal to -1 184%.
BGMD's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 009%.
BGMD has positive Gross Profit for the last twelve months.
BGMD has negative Free Cash Flow for the last twelve months.
BGMD has very high three-year average ROE (Return on Equity): 150%. The company is very efficient at transforming stockholders' equity into net income.
BGMD has negative three-year average ROIC (Return on Invested Capital): -1 587%. The company is not efficient at using invested capital to generate operating income.
BGMD's D/E (Debt to Equity) is very low and is equal to 0.
BGMD's Altman Z-Score is very low and is equal to -108.12.
BGMD doesn't generate enough operating income (-5m USD) to safely cover interest payments on its debt (119k USD).
Fundamental Analysis
BG Medicine Inc
Balance Sheet Decomposition
BG Medicine Inc
| Current Assets | 2m |
| Cash & Short-Term Investments | 1.5m |
| Receivables | 181k |
| Other Current Assets | 245k |
| Non-Current Assets | 182k |
| PP&E | 11k |
| Intangibles | 77k |
| Other Non-Current Assets | 94k |
| Current Liabilities | 1.2m |
| Accounts Payable | 558k |
| Accrued Liabilities | 345k |
| Other Current Liabilities | 277k |
| Non-Current Liabilities | 335k |
| Other Non-Current Liabilities | 335k |
Earnings Waterfall
BG Medicine Inc
|
Revenue
|
1.6m
USD
|
|
Cost of Revenue
|
-505k
USD
|
|
Gross Profit
|
1.1m
USD
|
|
Operating Expenses
|
-5.7m
USD
|
|
Operating Income
|
-4.6m
USD
|
|
Other Expenses
|
-2.3m
USD
|
|
Net Income
|
-7m
USD
|
Free Cash Flow Analysis
BG Medicine Inc
BGMD Profitability Score
Profitability Due Diligence
BG Medicine Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
BG Medicine Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
BGMD Solvency Score
Solvency Due Diligence
BG Medicine Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
BG Medicine Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BGMD Price Targets Summary
BG Medicine Inc
Ownership
BGMD Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BGMD Price
BG Medicine Inc
| Average Annual Return | 68.45% |
| Standard Deviation of Annual Returns | 204.74% |
| Max Drawdown | -100% |
| Market Capitalization | 5.5k USD |
| Shares Outstanding | 54 590 000 |
| Percentage of Shares Shorted | 10.01% |
Company Profile
BG Medicine Inc
Country
Industry
Market Cap
Dividend Yield
Description
BG Medicine, Inc. is a life sciences company. The company is headquartered in Foxboro, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
You don't have any saved screeners yet
